Pfizer’s BioNTech BNTX Stock Holding History

Pfizer’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,658,361	Closed	-$164M	–	19
2025 Q3	$164M	Sell	1,658,361 -2,000,000	-55%	-$214M	37.39%	1
2025 Q2	$390M	Hold	3,658,361	–	–	67.6%	1
2025 Q1	$333M	Hold	3,658,361	–	–	66.51%	1
2024 Q4	$417M	Buy	+3,658,361	New	+$417M	16.08%	2

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer's BNTX Position: Q4 2025 in Review

Pfizer sold out of BioNTech (BNTX) in Q4 2025, closing a stake of 1,658,361 shares — an estimated $164M sold.

Pfizer first reported a position in BNTX in Q4 2024 and held it in 4 quarters. The position peaked at $417M in Q4 2024. 284 funds tracked by Wall St. Rank hold BNTX as of Q4 2025.

Pfizer reported no remaining BioNTech position as of Q4 2025 after selling out during the quarter.
Pfizer sold 1,658,361 BioNTech shares in Q4 2025, an estimated $164M.
Pfizer first reported a position in BioNTech in Q4 2024 and held it in 4 quarters.
Pfizer's BioNTech position peaked at $417M in Q4 2024.
284 funds tracked by Wall St. Rank held BioNTech as of Q4 2025.

Based on Pfizer's 13F filing for Q4 2025, filed 12 Feb 2026.